<DOC>
	<DOCNO>NCT00791947</DOCNO>
	<brief_summary>This phase II prospective non-randomised clinical trial newly diagnose previously untreated adult patient age range 18-60 ( 67 ) year peripheral T-cell lymphoma . The treatment schedule consist three phase : induction high-dose consolidation , follow autologous stem cell rescue . There two different induction schedule : one patient age range 18-60 year one patient age 60 year .</brief_summary>
	<brief_title>A Nordic Phase II Study PTCL Based Dose-intensive Induction High-dose Consolidation With ASCT</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>Previously untreated patient newly diagnose peripheral Tcell lymphoma stage . However , patient nodal stage IA nonbulky disease ( &lt; 10cm ) treat individually discretion responsible physician . Following histologic subtypes ( WHO classification ) eligible inclusion study : Peripheral Tcell lymphoma , unspecified Angioimmunoblastic Tcell lymphoma NK/T nasaltype Tcell lymphoma Enteropathytype Tcell lymphoma Primary systemic , alknegative anaplastic large cell lymphoma ( Tor null phenotype ) Hepatosplenic Tcell lymphoma Subcutaneous panniculitislike Tcell lymphoma NB : Patients enter treatment program confirmation histopathological diagnosis referral center pathologist Age 1860 year . Patients age range 6167 year may include protocol discretion treat physician . form consent base oral write patient information ( Appendix I ) Primary cutaneous Tor nullcell anaplastic largecell lymphoma Alkpositive , primary systemic Tor nullcell anaplastic largecell lymphoma WHO Performance Status grade 4 ( Appendix II ) Patients severe cardiac ( i.e . severe heart failure require symptomatic treatment cardiac ejection fraction le 45 % ) , pulmonary , neurologic , psychiatric , renal , hepatic metabolic disease . Pregnancy . N.B : Women childbearing potential strongly advise apply appropriate contraceptive precaution entire treatment period . Patients concomitant malignancy except nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma . Patients seropositivity human immunodeficiency virus . Patients active therapeutically uncontrolled infection . Psychological , familial , social condition/s potentially hamper compliance followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>